Priyanka Singla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Priyanka Singla has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Lynn Kohan
Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, USA
5 shared publications Antje M Barreveld
Department of Anesthesiology, Tufts School of Medicine, Pain Medicine, Newton-Wellesley Hospital , Newton, MA
3 shared publicationsNabil Elkassabany
Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, USA
3 shared publicationsZachary L McCormick
Department of Physical Medicine and Rehabilitation, University of Utah School of Medicine , Salt Lake City, UT, 84132
3 shared publicationsAlexandra Adler
Department of Anesthesiology, Tufts University School of Medicine, Lowell General Hospital Pain Management , Lowell, MA, 01852
2 shared publicationsAnna Lepesteur Gianlorenco
Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital , Charlestown, MA
2 shared publications
Latest Publications
- 23 September 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Asymptomatic intrathecal baclofen pump catheter failure discovered during routine reservoir replacement: a case report
Background: Intrathecal baclofen (ITB) therapy effectively manages severe spasticity. While mechanical complications typically cause therapy loss or withdrawal, structural disruptions can remain completely occult due to anatomical adaptations. This report explores the unique management of an incidentally discovered catheter transection during routine reservoir exchange. Case presentation: A female patient in her 30s with cerebral palsy had been treated with ITB since 2011 without functional complaint, despite sluggish cerebrospinal fluid (CSF) flow noted at a 2019 pump exchange that did not prompt catheter revision. After relocating out of state, the patient returned in 2025 for a planned pump reservoir replacement, reporting no interval decline. Preoperative catheter port myelography was not successful due to failure of CSF aspiration from the catheter access port, and intraoperative exploration revealed the catheter was completely fractured at its fascial insertion point, despite the reported years of clinical stability. Fragment retrieval required partial laminectomy and multilayer dural repair; after new hardware placement and retitration, her therapeutic outcome improved dramatically. Conclusions: Subjective clinical efficacy is an unreliable proxy for system patency. Aging hardware configurations require proactive radiographic monitoring and targeted surgical revision to minimize the risk of withdrawal.
- 23 September 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Asymptomatic intrathecal baclofen pump catheter failure discovered during routine reservoir replacement: a case report
Background: Intrathecal baclofen (ITB) therapy effectively manages severe spasticity. While mechanical complications typically cause therapy loss or withdrawal, structural disruptions can remain completely occult due to anatomical adaptations. This report explores the unique management of an incidentally discovered catheter transection during routine reservoir exchange. Case presentation: A female patient in her 30s with cerebral palsy had been treated with ITB since 2011 without functional complaint, despite sluggish cerebrospinal fluid (CSF) flow noted at a 2019 pump exchange that did not prompt catheter revision. After relocating out of state, the patient returned in 2025 for a planned pump reservoir replacement, reporting no interval decline. Preoperative catheter port myelography was not successful due to failure of CSF aspiration from the catheter access port, and intraoperative exploration revealed the catheter was completely fractured at its fascial insertion point, despite the reported years of clinical stability. Fragment retrieval required partial laminectomy and multilayer dural repair; after new hardware placement and retitration, her therapeutic outcome improved dramatically. Conclusions: Subjective clinical efficacy is an unreliable proxy for system patency. Aging hardware configurations require proactive radiographic monitoring and targeted surgical revision to minimize the risk of withdrawal.
- 8 September 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (9) , 1088-1096
Uncommon indications in chronic pain for intrathecal drug delivery systems: a narrative review of the literature
Intrathecal drug delivery systems (IDDS) have been used successfully for a number of refractory chronic pain conditions. The most common pain indications for the use of IDDS include cancer-related pain and postlaminectomy syndrome. IDDS can also be used to treat a variety of other less common refractory pain conditions, including central neuropathic pain, peripheral neuropathic pain and craniofacial pain. The aim of this article was to review the existing literature on the efficacy and clinical utility of IDDS for the management of uncommon pain indications, including spinal cord injury-related pain, transverse myelitis, diabetic painful neuropathy, postherpetic neuralgia and craniofacial pain to inform clinicians on the state of the current evidence of IDDS use in these challenging pain conditions. PubMed, Embase, Web of Science, CINAHL and Cochrane databases were searched with keywords. Additionally, reference lists of retrieved articles and relevant reviews were manually screened to identify additional publications. Articles were screened for relevance using Covidence by three reviewers. Eligible studies included the use of IDDS for refractory uncommon pain conditions. Exclusion criteria included non-English studies, animal studies, studies that focused on non-pain indications and abstracts without accompanied full text. Given heterogeneity and largely descriptive data, findings were analyzed narratively by descriptive categories. The use of IDDS for refractory pain in patients with select pain conditions is supported primarily by observational studies and small clinical trials. Current evidence suggests that the IDDS may provide meaningful analgesia in carefully selected patients with central and peripheral pain, and facial neuropathic pain; however, the magnitude of pain relief and durability of response is variable. These findings are likely reflective of the limited evidence as a result of selective utilization of this therapy in clinical practice. Based on limited evidence, IDDS may provide meaningful clinical benefit in patients with refractory uncommon pain syndromes. Future research can help to define the use of IDDS in this challenging patient population.
- 8 September 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (9) , 1088-1096
Uncommon indications in chronic pain for intrathecal drug delivery systems: a narrative review of the literature
Intrathecal drug delivery systems (IDDS) have been used successfully for a number of refractory chronic pain conditions. The most common pain indications for the use of IDDS include cancer-related pain and postlaminectomy syndrome. IDDS can also be used to treat a variety of other less common refractory pain conditions, including central neuropathic pain, peripheral neuropathic pain and craniofacial pain. The aim of this article was to review the existing literature on the efficacy and clinical utility of IDDS for the management of uncommon pain indications, including spinal cord injury-related pain, transverse myelitis, diabetic painful neuropathy, postherpetic neuralgia and craniofacial pain to inform clinicians on the state of the current evidence of IDDS use in these challenging pain conditions. PubMed, Embase, Web of Science, CINAHL and Cochrane databases were searched with keywords. Additionally, reference lists of retrieved articles and relevant reviews were manually screened to identify additional publications. Articles were screened for relevance using Covidence by three reviewers. Eligible studies included the use of IDDS for refractory uncommon pain conditions. Exclusion criteria included non-English studies, animal studies, studies that focused on non-pain indications and abstracts without accompanied full text. Given heterogeneity and largely descriptive data, findings were analyzed narratively by descriptive categories. The use of IDDS for refractory pain in patients with select pain conditions is supported primarily by observational studies and small clinical trials. Current evidence suggests that the IDDS may provide meaningful analgesia in carefully selected patients with central and peripheral pain, and facial neuropathic pain; however, the magnitude of pain relief and durability of response is variable. These findings are likely reflective of the limited evidence as a result of selective utilization of this therapy in clinical practice. Based on limited evidence, IDDS may provide meaningful clinical benefit in patients with refractory uncommon pain syndromes. Future research can help to define the use of IDDS in this challenging patient population.
- 11 July 2026
- Published by Springer Nature
- p. 127-136
Radiofrequency Ablation
- Open Access
- 22 June 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (11) , 1231-1265
American Academy of Pain Medicine consensus guidelines on neuromodulation technologies and neurocomputer interfaces for pain management and functional recovery
Objective: To provide an evidence-based framework for healthcare professionals to use neuromodulation technologies to restore neuromuscular function and relieve pain. Methods: An expert panel, convened by the American Academy of Pain Medicine Foundation, conducted a literature review of English-language studies published between 2015 and 2025 using PubMed, the Cochrane Library, Web of Science, and Scopus (detailed in Supplementary Material S2). The panel screened abstracts, extracted key data, and evaluated evidence quality using a modified United States Preventive Services Task Force criteria. A Delphi process was used to achieve expert consensus on clinical recommendations for various neuromodulation technologies: artificial intelligence-guided and robotic rehabilitation systems, virtual/augmented reality interfaces, brain-computer interfaces, electrical nerve stimulation (encompassing peripheral nerve stimulation transcutaneous electrical stimulation), vagus nerve stimulation, multifidus neurostimulation, surgery (eg, regenerative peripheral nerve interface), scrambler therapy, spinal cord stimulation for motor restoration, and transcranial magnetic stimulation. Results: The panel provided clinical recommendations and discussed mechanisms of action, evidence, and clinical considerations for each intervention. Evidence for these technologies is evolving, with some showing promising results in areas like improving upper limb function post-stroke, improving functional spine-related outcomes, and reducing chronic pain. Conclusions: Neuromodulation technologies offer a promising approach for neuromuscular restoration, focusing on interventions that promote functional recovery rather than solely providing symptomatic care. Areas for future research include more high-quality, large-scale studies with consistent outcome measures.
- 22 June 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (11) , 1231-1265
Open AccessAmerican Academy of Pain Medicine consensus guidelines on neuromodulation technologies and neurocomputer interfaces for pain management and functional recovery
Objective: To provide an evidence-based framework for healthcare professionals to use neuromodulation technologies to restore neuromuscular function and relieve pain. Methods: An expert panel, convened by the American Academy of Pain Medicine Foundation, conducted a literature review of English-language studies published between 2015 and 2025 using PubMed, the Cochrane Library, Web of Science, and Scopus (detailed in Supplementary Material S2). The panel screened abstracts, extracted key data, and evaluated evidence quality using a modified United States Preventive Services Task Force criteria. A Delphi process was used to achieve expert consensus on clinical recommendations for various neuromodulation technologies: artificial intelligence-guided and robotic rehabilitation systems, virtual/augmented reality interfaces, brain-computer interfaces, electrical nerve stimulation (encompassing peripheral nerve stimulation transcutaneous electrical stimulation), vagus nerve stimulation, multifidus neurostimulation, surgery (eg, regenerative peripheral nerve interface), scrambler therapy, spinal cord stimulation for motor restoration, and transcranial magnetic stimulation. Results: The panel provided clinical recommendations and discussed mechanisms of action, evidence, and clinical considerations for each intervention. Evidence for these technologies is evolving, with some showing promising results in areas like improving upper limb function post-stroke, improving functional spine-related outcomes, and reducing chronic pain. Conclusions: Neuromodulation technologies offer a promising approach for neuromuscular restoration, focusing on interventions that promote functional recovery rather than solely providing symptomatic care. Areas for future research include more high-quality, large-scale studies with consistent outcome measures.
- 17 June 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (10) , 1151-1153
Beyond postdural puncture headache: differential diagnosis and complications after labor epidural analgesia
- 17 June 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (10) , 1151-1153
Beyond postdural puncture headache: differential diagnosis and complications after labor epidural analgesia
- 22 February 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (8) , 863-866
CMS proposed restrictions on peripheral nerve blocks and procedures for chronic pain: clinical, ethical, and policy implications for millions of Americans
- 22 February 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (8) , 863-866
CMS proposed restrictions on peripheral nerve blocks and procedures for chronic pain: clinical, ethical, and policy implications for millions of Americans